Apotex Health Corp. (TSX:APTX)

Revenue by Segment

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Conventional Generics	1.78B	1.87B	1.79B
Specialty Generics	1.15B	976.30M	784.21M
Brands & Biosimilars	558.70M	500.96M	369.76M
Total	3.49B	3.35B	2.94B

Revenue by Geography

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Canada	1.43B	1.27B	1.08B
United States (U.S.)	1.79B	1.81B	1.58B
Other	269.38M	271.05M	282.02M
Total	3.49B	3.35B	2.94B

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 18, 2026

Data Sources Report a data error